OakChart

Bioventus Inc

BVSHealthcare·Medical Devices·USA·Small·NASD·Nov 11 • 3:59 PM ET

10.99-0.19 (-1.70%)
2026-11-12 02:16 CET
Market cap
765.54 USD m
Revenue, TTM
585.64 USD m
Net income, TTM
57.30 USD m
Free cash flow, TTM
84.29 USD m
EPS diluted, TTM
0.81
P/E
13.53
Compare

Price

BVS against its 20, 50 and 200-day averages
2050200beatearnings
8.0010.0012.0014.0016.001.3M2.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BVSclose 10.9920-day 13.0450-day 13.28200-day 11.0310.9952w high

30.9% under the 52-week high of 15.89 on 5 Aug 2026. 52-week low 6.47 on 21 Nov 2025. Last 15 sessions, 51.9% high to low

Volume 0.86× normal · the line is the 50-bar volume average

Profile

BVS
52-week range, 48% of the way up
6.4715.89

Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.

IndexRUT
Employees930
IPOFeb 11, 2021
Beta0.65
ATR, 14d0.73
Rel volume0.86
Short float6.38%
Insider own30.83%
Inst own59.59%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap926.03M
Enterprise Value1.19B
Income57.30M
Sales585.64M
Book/sh3.51
Cash/sh0.36
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees930
IPOFeb 11, 2021

Ratios

P/E13.53
Forward P/E12.38
PEG0.82
P/S1.58
P/B3.13
P/C30.15
P/FCF10.99
EV/EBITDA11.54
EV/Sales2.03
Quick Ratio1.16
Current Ratio1.68
Debt/Eq1.02
LT Debt/Eq0.92
Option/ShortYes / Yes

Earnings

EPS (ttm)0.81
EPS next Y0.89
EPS next Q0.22
EPS this Y12.94%
EPS next Y15.60%
EPS next 5Y15.01%
EPS past 3/5Y- 33.74%
Sales past 3/5Y3.52% 12.08%
EPS Y/Y TTM623.68%
Sales Y/Y TTM3.87%
EPS Q/Q80.35%
Sales Q/Q2.73%
EarningsNov 02 AMC
EPS/Sales Surpr.13.64% -4.73%

Ownership

Insider Own30.83%
Insider Trans0.00%
Inst Own59.59%
Inst Trans6.30%
ROA8.33%
ROE28.18%
ROIC12.41%
Gross Margin67.93%
Oper. Margin10.08%
Profit Margin9.78%
SMA20-15.71%
SMA50-17.22%
SMA200-0.39%
Trades-

Technical

Shs Outstand68.45M
Shs Float47.37M
Short Float6.38%
Short Ratio5.58
Short Interest3.02M
52W High15.89 -30.85%
52W Low6.47 69.86%
Volatility6.05% 5.13%
ATR (14)0.73
RSI (14)34.87
Beta0.65
Rel Volume0.86
Avg Volume541.56K
Volume463,303

Performance

Perf Week-3.77%
Perf Month-18.95%
Perf Quarter-20.88%
Perf Half Y5.67%
Perf YTD47.72%
Perf Year42.73%
Perf 3Y212.22%
Perf 5Y-32.54%
Perf 10Y-
Recom1.00
Target Price16.60
Prev Close11.18
Price10.99
Change %-1.70%

Analyst ratings

latest 10 of 17
DateActionAnalystRating changeTargetImplied
Mar 27, 2026InitiatedCCJS SecuritiesMarket Outperform$14+27.4%
Feb 09, 2026InitiatedBBarrington ResearchOutperform$13+18.3%
Jul 07, 2025InitiatedCCantor FitzgeraldOverweight$12+9.2%
Dec 17, 2024UpgradeJJP MorganUnderweight → Neutral$12 → $13+18.3%
Dec 07, 2023UpgradeCCanaccord GenuityHold → Buy$7-36.3%
Aug 09, 2023UpgradeCCraig HallumHold → Buy$4 → $6-45.4%
Nov 22, 2022DowngradeCCraig HallumBuy → Hold
Nov 09, 2022DowngradeJJP MorganOverweight → Underweight
Nov 09, 2022DowngradeCCanaccord GenuityBuy → Hold$18 → $6-45.4%
Mar 15, 2022InitiatedCCraig HallumBuy$30+173.0%

Peers

Mkt cap
TickerCompanyMkt cap
OFIXOrthofix Medical Inc292.66M
ANIKAnika Therapeutics Inc186.86M
CNMDConmed Corp1.51B
ZBHZimmer Biomet Holdings Inc20.34B
ENOVEnovis Corp1.65B
IARTIntegra Lifesciences Holdings Corp1.15B
XTNTXtant Medical Holdings Inc38.99M
VCELVericel Corp3.03B
MDXGMimedx Group Inc484.47M
SNWVSanuwave Health Inc15.31M

Insider trading

latest 14 of 26
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Bartholdson John A.DirectorJun 02 '26Option Exercise0.0032,2820111,902Jun 04 05:06 PM
SUTTER MARTIN PDirectorJun 02 '26Option Exercise0.0032,2820117,523Jun 04 04:48 PM
STALNECKER SUSAN MDirectorJun 02 '26Option Exercise0.0032,2820138,239Jun 04 04:47 PM
NOHRA GUY PDirectorJun 02 '26Option Exercise0.0032,2820148,892Jun 04 04:47 PM
NEELS GUIDO JDirectorJun 02 '26Option Exercise0.0032,2820117,523Jun 04 04:47 PM
McMurry-Heath MichelleDirectorJun 02 '26Option Exercise0.0032,282077,279Jun 04 04:47 PM
Ladone Mary KayDirectorJun 02 '26Option Exercise0.0032,2820111,263Jun 04 04:46 PM
HAWKINS WILLIAM ADirectorJun 02 '26Option Exercise0.0039,7890297,640Jun 04 04:46 PM
Cowdy Philip G.DirectorJun 02 '26Option Exercise0.0032,282043,982Jun 04 04:46 PM
Beyer PatDirectorJun 02 '26Option Exercise0.0032,2820108,718Jun 04 04:45 PM
Singleton Mark LeonardSVP & CFOApr 10 '26Option Exercise0.0013,0000182,981Apr 14 06:18 PM
CHURCH KATRINA JSVP & Chief Compliance OfficerApr 10 '26Option Exercise0.004,300066,032Apr 14 06:18 PM
D'Adamio AnthonySVP & General CounselApr 10 '26Option Exercise0.009,9250157,967Apr 14 06:17 PM
Singleton Mark LeonardSVP & CFOMar 20 '26Option Exercise0.0018,6250178,072Mar 24 04:59 PM

Held by

AUM
TickerCompanyAUM
AVUVAvantis U.S. Small Cap Value ETFAUM: 32.39B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M

News

latest 14 of 200
  • Bioventus Matches On EPS But Cuts Its Revenue Outlook As Debt Paydown, Not Operations, Drives Earnings Growth (Earnings Whispers) -16.77%
  • Bioventus: Q3 Earnings Snapshot (Associated Press)
  • Bioventus Reports Third Quarter Financial Results (GlobeNewswire)
  • Bioventus Must Prove Its Second-Half Rebound While A Strategic Review Hangs Overhead (Earnings Whispers)
  • Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026 (GlobeNewswire)
  • Bioventus Inc (BVS) (Q2 2026) Earnings Call Highlights: Strategic Review and Strong HA Growth ... (GuruFocus.com) +13.71% -8.39%
  • Bioventus: Q2 Earnings Snapshot (Associated Press)
  • Bioventus Reports Second Quarter Financial Results (GlobeNewswire)
  • Bioventus to Report Second Quarter of Fiscal Year 2026 Financial Results on August 5, 2026 (GlobeNewswire)
  • Did Bioventus Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
  • The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts (PR Newswire)
  • Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference (GlobeNewswire)
  • Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It (PR Newswire)
  • Bioventus: Q1 Earnings Snapshot (Associated Press)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-020.1700.1500.080142.44149.515
2026Q22026-08-050.2200.2160.472153.21155.445
2026Q12026-05-060.1500.0690.045132.09129.925
2025Q42026-03-050.2400.2160.213157.9154.953
2025Q32025-11-040.1500.1050.046138.65138.193
2025Q22025-08-060.2100.1570.109147.66145.864
2025Q12025-05-060.0800.025-0.040123.88122.713
2024Q42025-03-110.1500.083-0.002153.64145.163
2024Q32024-11-050.0600.016-0.074138.96133.243
2024Q22024-08-060.1900.067-0.375151.22137.63
2024Q12024-05-070.070-0.067-0.072129.46118.373
2023Q42024-03-120.0700.019-0.097135.42123.963
2023Q32023-11-070.050-0.020-0.116120.791193
2023Q22023-08-080.140-0.003-0.059137.07129.233
2023Q12023-05-16-0.260-0.150-2.240119.06116.574
2022Q42023-03-31-0.0600.048-0.516125.83132.594

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY1.0150.8600.077321.12320.87
2021FY0.7500.9010.325430.9430.39
2022FY0.1700.258-2.585512.12521.72
2023FY0.020-0.301-2.494512.35500.9
2024FY0.4900.402-0.560573.28564.94
2025FY0.6800.6610.330568.09565.88
2026FY-0.768--594.93
2027FY-0.888--633.09
2028FY-1.034--678.36
2029FY-1.040--719.73
2030FY-1.160--775.17

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-03504165.67163.39170.76
2026Q4S2026-11-02500169.96168.35170.76
2026Q4S2026-10-28500169.96168.35170.76
2026Q4S2026-09-11510169.96168.35170.76
2026Q4S2026-08-21510169.97168.35170.8
2026Q4S2026-08-14510169.96168.35170.8
2026Q4S2026-08-13500169.6168.35170.7
2026Q4S2026-08-05500169.29168.35170.7
2026Q4S2026-07-27500168.95167.67169.8
2026Q4S2026-07-03500169.08168.35169.8
2026Q4S2026-07-02500169.09168.35169.8
2026Q4S2026-06-12500168.95167.67169.8
2026Q4S2026-05-21500168.95167.67169.8
2026Q4S2026-05-19500169.09168.35169.8

Estimate history

EPS, annual-0.128-0.317-0.0120.0770.325-2.585-2.494-0.560.330.8122
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.074-0.002-0.040.1090.0460.2130.0450.4720.083
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual292.059319.177340.141321.161430.898512.117512.345573.28568.087585.64
Period201720182019202020212022202320242025TTM
Sales, quarterly138.964153.642123.876147.66138.651157.9132.089153.208142.442
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual56.82556.82556.82556.82559.54962.06363.26765.75867.09868.455
Period201720182019202020212022202320242025MRQ
Shares, quarterly65.33765.75866.23166.88566.97467.09867.63968.21268.455
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue585.64568.09573.28512.35512.12430.90321.16340.14319.18
Cost of Goods Sold Incl. D&A187.79185.66192.71192.99190.78140.4195.1298.8592.79
Gross Profit397.85382.43380.57319.35321.33290.49226.04241.29226.38
Selling, General and Administrative Excl. Other338.81323.88330.04303.34329.96239.31193.00203.34197.78
Research and Development12.0812.1113.9513.4523.8515.1911.1711.058.09
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income59.0458.5550.5416.01-8.6251.1933.0437.9528.60
Interest Expense17.4626.4938.7940.6818.425.507.5121.5819.17
Unusual Expense2.214.3260.7494.16152.2133.6212.806.753.10
Net Income Before Taxes40.1325.71-52.34-121.11-189.037.6215.919.696.11
Income Taxes-24.20-1.56-5.290.09-44.37-1.971.191.581.66
Consolidated Net Income64.3327.27-47.05-121.20-144.659.598.836.564.44
Net Income From Continuing Operations57.3022.73-36.12-96.74-103.9219.3810.527.114.44
Net Income57.3022.73-36.12-156.23-158.7019.384.38-0.66-17.99
EPS (Recurring)0.810.370.10-1.44-0.850.720.230.07-0.28
EPS (Basic, Before Extraordinaries)0.850.34-0.56-2.49-2.590.330.08-0.01-0.32
EPS (Diluted)0.810.33-0.56-2.49-2.590.330.08-0.01-0.32
EBITDA103.20105.56100.0973.3852.7889.8761.6968.2657.84
Non-Operating Income (Expense)0.76-2.04-3.35-2.29-9.77-4.443.180.07-0.23
Other After Tax Adjustments0.000.000.000.000.000.00-5.89-1.550.00
Stock Option Compensation Expense12.669.6312.832.1513.8914.497.387.9211.32
Price To Earnings Ratio13.7713.77---31.0829.52--
Price To Sales Ratio1.710.901.180.640.312.00---
Gross Margin67.9367.3266.3962.3362.7567.4270.3870.9470.93
Operating Margin10.0810.318.823.13-1.6811.8810.2911.168.96
Net Margin9.784.00-6.30-30.49-30.994.501.36-0.19-5.64
Shares Outstanding68.4567.1065.7663.2762.0659.5556.8356.8356.83
Market Capitalization765.54765.54686.36331.83202.901,090.011,068.19--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue142.44153.21132.09157.90138.65147.66123.88153.64
Cost of Goods Sold Incl. D&A46.3648.5842.4350.4145.8247.0142.4152.75
Gross Profit96.08104.6289.66107.4892.83100.6581.46100.89
Selling, General and Administrative Excl. Other86.3885.8980.7785.7780.7382.0376.4988.58
Research and Development3.443.172.473.012.923.173.013.25
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income9.7018.748.8921.7112.1018.624.9712.31
Interest Expense3.764.074.335.316.187.497.519.00
Unusual Expense0.00-0.390.472.131.180.250.022.83
Net Income Before Taxes6.1615.314.5214.144.6710.31-3.420.23
Income Taxes-0.70-20.900.57-3.170.661.04-0.100.55
Consolidated Net Income6.8636.203.9517.324.019.27-3.32-0.32
Net Income From Continuing Operations5.9933.443.1114.763.157.46-2.64-0.16
Net Income5.9933.443.1114.763.157.46-2.64-0.16
EPS (Recurring)0.080.470.050.230.060.11-0.040.03
EPS (Basic, Before Extraordinaries)0.090.490.050.220.050.11-0.04-0.00
EPS (Diluted)0.080.470.040.210.050.11-0.04-0.00
EBITDA20.0229.6820.0933.4123.5130.6716.8424.72
Non-Operating Income (Expense)0.220.250.43-0.14-0.08-0.56-0.86-0.25
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.763.982.582.341.972.881.911.50
Price To Earnings Ratio13.5322.9027.8666.25----
Price To Sales Ratio1.711.191.090.910.810.821.051.20
Gross Margin67.4568.2967.8868.0766.9568.1665.7665.66
Operating Margin6.8112.236.7313.758.7312.614.018.01
Net Margin4.2021.832.369.342.285.05-2.13-0.10
Shares Outstanding68.4568.2167.6467.1066.9766.8966.2365.76
Market Capitalization752.53639.54615.07498.31447.51439.29605.34686.36

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments51.2441.5836.9630.1949.2186.8464.5242.77-
Short Term Receivables128.48127.47123.05136.56125.0588.3685.3973.04-
Inventories82.2492.4791.3384.7761.6929.1227.3327.40-
Other Current Assets10.8914.0816.6621.0627.167.475.805.14-
Total Current Assets272.84275.61268.00272.57263.10211.79183.03148.35-
Net Property, Plant & Equipment27.0233.5249.9644.1540.1721.8419.764.76-
Total Investments and Advances0.000.000.000.0050.000.000.000.00-
Intangible Assets375.88412.19489.81647.31842.82241.45266.31286.83-
Deferred Tax Assets5.524.75-0.000.48----
Other Assets2.291.893.14408.6229.2919.383.312.78-
Total Assets683.56727.96810.911,372.651,225.86494.47472.41442.72-
Short Term Debt Incl. Current Port. of LT Debt19.2131.2631.9136.6121.5416.9611.865.29-
Accounts Payable10.9323.6923.0436.7016.914.426.448.21-
Income Tax Payable5.133.874.752.578.142.432.562.03-
Other Current Liabilities125.11151.58115.81228.14134.2698.7768.1749.90-
Total Current Liabilities160.38210.40175.50304.02180.86122.5989.0265.43-
Long Term Debt292.14324.80377.57399.37354.68187.49202.49189.63-
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Deferred Tax Liabilities0.430.561.212.25133.523.363.873.96-
Other Liabilities2.166.5935.51254.8023.0136.8731.4138.44-
Total Liabilities455.11542.35589.79960.43692.07350.31326.79297.46-
Non-Equity Reserves0.000.000.000.000.000.000.000.00-
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00-
Common Equity184.10147.94173.59325.24458.92142.24142.98145.27-
Total Shareholders Equity184.10147.94173.59325.24458.92142.24142.98145.27-
Accumulated Minority Interest44.3437.6647.5386.9874.861.922.630.00-
Total Equity228.45185.60221.12412.22533.79144.16145.62145.27-
Total Liabilities & Stockholders Equity683.56727.96810.911,372.651,225.86494.47472.41442.72-
Book Value Per Share2.742.252.745.247.712.502.522.56-
Tangible Book Value Per Share-2.86-4.02-5.00-5.19-6.45-1.75-2.17-2.49-
Full-Time Employees9309309701,1201,200700---
Price to Book Ratio3.184.611.870.591.885.30---
Return on Assets3.22-4.70-8.86-8.002.252.181.55--
Return on Equity13.69-22.47-39.47-26.506.457.374.93--
Return on Invested Capital4.77-7.64-28.35-21.902.383.191.53-3.64-
Quick Ratio1.190.871.010.621.111.491.751.85-
Current Ratio1.701.311.530.901.451.732.062.27-

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income64.3327.27-47.05-195.62-144.659.5914.728.114.44
Depreciation44.1647.0149.5557.3755.4034.8828.6430.3229.24
Other Funds (Non Cash)17.0914.4452.28159.16152.101.5613.6416.208.73
Funds from Operations101.8187.8249.4018.5216.1936.2756.4954.2842.34
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-15.07-13.84-11.78-3.18-29.73-13.2815.31-13.572.85
Cash from Operating Activities86.7473.9837.6215.34-13.5422.9971.8040.7145.19
Capital Expenditures-2.45-2.56-1.72-7.36-11.52-20.89-20.67-8.34-6.06
Net Assets From Acquisitions0.00-0.690.000.000.00-262.870.000.000.00
Sale of Fixed Assets and Businesses0.000.0024.6834.670.000.000.000.430.00
Purchase or Sale of Investments-1.500.000.000.000.000.000.000.000.00
Purchase of Investments-1.500.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.00--
Other Uses0.000.000.00-11.51-104.920.000.000.00-0.04
Other Sources0.000.000.000.000.000.000.170.000.00
Cash from Investing Activities-5.45-3.2522.9615.81-116.44-283.76-20.50-7.91-6.10
Cash Dividends Paid0.000.000.000.000.00-0.37-19.89-9.14-7.85
Change in Capital Stock2.902.072.440.785.82107.570.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock2.902.072.440.785.82107.570.000.000.00
Proceedsfrom Stock Options2.902.072.440.785.82107.570.000.000.00
Issuance or Reduction of Debt, Net-92.55-42.91-59.58-26.9359.62166.20-10.00-1.81-5.41
Change in Long Term Debt-92.55-42.91-59.58-26.9359.62166.20-10.00-1.81-5.41
Issuance of Long Term Debt0.7076.910.0060.34104.66257.450.00197.770.00
Reduction of Long Term Debt-93.25-119.82-59.58-87.26-45.04-91.25-10.00-199.58-5.41
Net Financing Active Other Cash Flow-2.25-20.613.74-0.51-3.37-0.040.320.000.00
Other Financing Activities Uses-2.25-20.61-0.76-0.51-3.37-0.040.000.000.00
Cash from Financing Activities-91.91-61.44-53.40-26.6562.08273.37-29.57-10.95-13.26
Exchange Rate Effect-0.830.37-2.560.630.52-0.230.59-0.10-0.16
Net Change in Cash-11.469.664.625.13-67.3812.3722.3221.7525.67
Free Cash Flow84.2971.4136.617.98-23.5815.6267.7138.3742.63
Preferred Dividends (Cash Flow)-0.000.000.000.000.00---
Price to Free Cash Flow11.887.1818.5141.36-56.57---
Deferred Taxes & Investment Tax Credit--0.91-5.39-2.38-46.66-9.76-0.51-0.35-0.08

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments30.7129.4635.8551.2442.1632.91
Short Term Receivables138.23138.41120.53128.48130.40132.37
Inventories83.1079.8183.1982.2496.2796.47
Other Current Assets13.519.8610.2610.8912.0613.46
Total Current Assets265.54257.53249.81272.84280.90275.20
Net Property, Plant & Equipment23.5424.7525.9827.0228.8130.74
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets351.39358.51367.12375.88384.86394.42
Deferred Tax Assets29.5429.055.525.524.754.75
Other Assets3.423.512.102.292.271.69
Total Assets673.43673.35650.54683.56701.59706.79
Short Term Debt Incl. Current Port. of LT Debt22.8922.8922.9119.2115.6647.77
Accounts Payable25.7920.2024.0510.9326.6524.25
Income Tax Payable5.726.164.815.134.834.64
Other Current Liabilities103.31103.2096.33125.11114.61109.02
Total Current Liabilities157.70152.45148.09160.38161.75185.68
Long Term Debt221.26240.85265.51292.14325.51312.89
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.570.570.570.430.790.65
Other Liabilities2.022.062.102.166.296.27
Total Liabilities381.56395.93416.27455.11494.34505.49
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity240.50228.31188.90184.10166.10161.24
Total Shareholders Equity240.50228.31188.90184.10166.10161.24
Accumulated Minority Interest51.3849.1145.3644.3441.1640.06
Total Equity291.87277.41234.26228.45207.25201.30
Total Liabilities & Stockholders Equity673.43673.35650.54683.56701.59706.79
Book Value Per Share3.513.352.792.742.482.41
Tangible Book Value Per Share-1.62-1.91-2.63-2.86-3.27-3.49
Full-Time Employees---930--
Price to Book Ratio3.133.383.333.002.782.96
Return on Assets8.337.894.243.221.06-0.02
Return on Equity28.1827.9616.9013.694.97-0.10
Return on Invested Capital1.307.130.693.100.641.57
Quick Ratio1.161.171.131.191.140.96
Current Ratio1.681.691.691.701.741.48

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income6.8636.203.9517.324.019.27
Depreciation10.3110.9511.2111.6911.4012.05
Other Funds (Non Cash)4.915.183.823.183.884.10
Funds from Operations21.5930.0419.1131.0619.4225.46
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.94-10.17-10.186.2110.680.48
Cash from Operating Activities20.6619.878.9337.2730.1025.94
Capital Expenditures-1.83-0.96-0.57-0.58-0.47-0.68
Net Assets From Acquisitions0.000.000.000.000.00-0.69
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.00-1.500.000.000.000.00
Purchase of Investments0.00-1.500.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-1.83-2.46-0.57-0.58-0.47-1.37
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.420.850.120.510.101.32
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.420.850.120.510.101.32
Proceedsfrom Stock Options1.420.850.120.510.101.32
Issuance or Reduction of Debt, Net-18.75-23.75-22.00-28.05-19.86-5.00
Change in Long Term Debt-18.75-23.75-22.00-28.05-19.86-5.00
Issuance of Long Term Debt0.000.000.000.7061.210.00
Reduction of Long Term Debt-18.75-23.75-22.00-28.75-81.07-5.00
Net Financing Active Other Cash Flow-0.25-0.54-1.26-0.21-0.22-10.98
Other Financing Activities Uses-0.25-0.54-1.26-0.21-0.22-10.98
Cash from Financing Activities-17.58-23.43-23.14-27.75-19.98-14.66
Exchange Rate Effect0.01-0.37-0.610.13-0.390.20
Net Change in Cash1.25-6.39-15.399.079.2510.11
Free Cash Flow20.3218.918.3636.6929.6225.25
Price to Free Cash Flow11.887.406.267.228.5713.61

Revenue breakdown

Pain Treatments2024: 261.29M 2025: 279.06M
Restorative Therapies2024: 122.74M 2025: 85.37M
Surgical Solutions2024: 189.26M 2025: 203.65M
Non-US2024: 66.47M 2025: 65.99M
United States2024: 506.81M 2025: 502.10M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.38%3.0M47.4M565.50K
2026-10-156.73%3.2M47.3M596.89K
2026-09-306.69%3.2M47.3M666.19K
2026-09-156.20%2.9M47.3M700.79K
2026-08-315.48%2.6M47.1M733.36K
2026-08-144.96%2.3M47.1M761.24K
2026-07-315.39%2.5M47.1M682.67K
2026-07-155.85%2.7M46.7M643.55K
2026-06-304.68%2.2M46.7M589.52K
2026-06-154.13%1.9M46.7M561.97K
2026-05-293.95%1.8M46.7M516.74K
2026-05-153.35%1.6M47.0M447.30K
2026-04-303.15%1.5M46.5M410.30K
2026-04-152.91%1.3M46.3M375.22K
2026-03-313.32%1.5M46.3M336.83K
2026-03-133.08%1.4M46.3M291.69K
2026-02-273.12%1.4M46.0M262.99K
2026-02-133.38%1.6M46.0M273.32K
2026-01-303.36%1.5M46.0M303.15K
2026-01-153.68%1.7M46.0M301.18K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.506.6010.700.0024.3180.000.000.988-0.0160.001
call5.004.108.200.0010.9090.000.000.977-0.0160.001
call7.502.105.700.006.8190.000.000.957-0.0140.002
call10.000.052.750.003.4440.000.000.681-0.1440.006
call12.500.002.000.013.7391831.000.528-0.1440.007
call15.000.002.150.064.67274.000.000.475-0.1800.007
call17.500.002.150.335.36413.000.000.445-0.2050.007
call20.000.002.150.005.9120.000.000.425-0.2240.007
call22.500.000.950.004.5750.000.000.268-0.1470.006
call25.000.001.550.004.9410.000.000.257-0.1560.006
put2.500.001.300.005.1530.000.00-0.012-0.0160.001
put5.000.002.150.042.86520.000.00-0.023-0.0150.001
put7.500.000.050.053.0441.000.00-0.145-0.0670.004
put10.000.002.200.134.17712.000.00-0.319-0.1430.006
put12.501.052.451.652.19619.000.00-0.472-0.1430.007
put15.002.106.003.904.6790.000.00-0.525-0.1790.007
put17.504.308.500.005.3740.000.00-0.555-0.2030.007
put20.006.8011.000.005.9280.000.00-0.575-0.2220.007
put22.509.3013.300.006.0860.000.00-0.731-0.1470.006
put25.0011.8015.200.005.5170.000.00-0.742-0.1550.006

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0210-QQuarterly report pursuant to Section 13 or 15(d)2026-09-26SEC
2026-11-028-KCurrent report2026-11-02SEC
2026-10-27SCHEDULE 13G/ASEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-27SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-27SCHEDULE 13GSEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-048-KCurrent report2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-05-29SDSpecialized Disclosure ReportSEC
2026-05-218-KCurrent report2026-05-21SEC
2026-05-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-03-28SEC
2026-05-068-KCurrent report2026-05-06SEC
2026-04-22ARSAnnual report to security holders. 2025-12-31SEC
2026-04-22DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-22DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342025-12-31SEC
2026-04-144Statement of changes in beneficial ownership of securities2026-04-10SEC
2026-04-144Statement of changes in beneficial ownership of securities2026-04-10SEC
2026-04-144/A2021-04-01SEC
2026-04-144/A2021-02-11SEC
2026-04-144Statement of changes in beneficial ownership of securities2026-04-10SEC
2026-03-244Statement of changes in beneficial ownership of securities2026-03-20SEC
2026-03-174Statement of changes in beneficial ownership of securities2025-03-14SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-0300105.44K1
2026-020000
2026-010000
2025-120075.66K1
2025-1100131.25K1

Institutional holders

Manager% owned
Essex Woodlands Management, Inc.19.06%
Nantahala Capital Management, LLC17.71%
Juniper Investment Company, LLC10.24%
BlackRock, Inc.5.07%
VANGUARD CAPITAL MANAGEMENT LLC2.59%
ROYCE & ASSOCIATES LP2.36%
GEODE CAPITAL MANAGEMENT, LLC2.04%
AMERICAN CENTURY COMPANIES INC2.00%
DIMENSIONAL FUND ADVISORS LP1.81%
STATE STREET CORP1.63%

Funds

Fund% owned
Avantis U.S. Small Cap Value ETF2.23%
iShares Russell 2000 ETF1.85%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.72%
Royce Small-Cap Opportunity Fund1.27%
Oberweis Micro-Cap Fund1.01%
VANGUARD EXTENDED MARKET INDEX FUND0.81%
Fidelity Small Cap Index Fund0.78%
Old Westbury Small & Mid Cap Strategies Fund0.76%
iShares Russell 2000 Growth ETF0.67%
Fidelity Enhanced Small Cap Core ETF0.64%

OakChart. BVS. Cached 15 minutes.